Trevi Therapeutics, Inc. (TRVI) Stock Score, Valuation & Financial Research

Trevi Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TRVI

Trevi Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 14.49. These figures are a research snapshot, not a buy or sell recommendation.

What Trevi Therapeutics, Inc. does

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Trevi Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of its investigational therapy, Haduvio, with the goal of obtaining regulatory approval and eventually commercializing the product to treat chronic pruritus and chronic cough.

Products and services

Haduvio (oral nalbuphine ER), an investigational oral extended-release formulation of nalbuphine, a small molecule opioid mixed agonist-antagonist.

Brands and product families

Haduvio — Investigational oral extended-release formulation of nalbuphine. Source

Customer types

Patients with chronic pruritus; Patients with chronic cough.

Suppliers, materials and equipment

Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug product. Source

Business strengths to evaluate

Proprietary clinical-stage pipeline focused on Haduvio Source

Business risks and research considerations

History of operating losses and expectation of future losses Source
Dependence on the success of a single product candidate, Haduvio Source
Significant capital requirements for clinical development and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TRVI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 14.49
Market capitalization:: 2.06B (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -51.11M
Free cash flow:: USD -42.1M
Cash:: USD 54.3M
Total debt:: USD 605K
EPS:: USD -0.34

What stands out

Free cash flow is USD -42.1M, negative for the stored period.
The balance sheet shows USD 54.3M of cash versus USD 605K of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Cash exceeds debt by USD 53.7M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TRVI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can TRVI fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is TRVI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for TRVI to reach sustainable profitability?
What does the current fundamental change risk warning mean for the reliability or interpretation of TRVI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research TRVI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.